Quote | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Last: | $9.62 |
---|---|
Change Percent: | 0.0% |
Open: | $9.59 |
Close: | $9.62 |
High: | $10 |
Low: | $9.28 |
Volume: | 347,759 |
Last Trade Date Time: | 06/10/2024 03:00:00 am |
News | Larimar Therapeutics Inc. (NASDAQ:LRMR)
2024-06-06 10:13:02 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Bird flu death in Mexico linked to strain not seen in humans before FDA advisors unanimously agree on COVID JN.1-lineage vaccine for fall Moderna...
2024-05-31 16:11:42 ET Summary Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $...
Message Board Posts | Larimar Therapeutics Inc. (NASDAQ:LRMR)
Subject | By | Source | When |
---|---|---|---|
could probably get through approval on just 25 | magacrew2020 | investorshub | 02/28/2023 11:21:47 PM |
znewcar1: LRMR 24% v2,7M c2.89 f17,7M H3.58 ML1.53 | znewcar1 | investorshangout | 08/19/2022 12:18:48 AM |
The company said it received feedback from the | subslover | investorshub | 08/12/2022 12:58:00 PM |
I voted NO on the 2022 Annual Meeting | JJJ54 | investorshub | 04/21/2022 1:11:30 AM |
Interesting. | DarkPool | investorshub | 02/14/2022 10:08:23 PM |
News, Short Squeeze, Breakout and More Instantly...
Larimar Therapeutics Inc. Company Name:
LRMR Stock Symbol:
NASDAQ Market:
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday...
START is a new milestone-driven program designed to accelerate development of novel therapies intended to address an unmet medical need for rare diseases Nomlabofusp was selected based on potential for clinical benefit in a rare neurodegenerative disease and demonstrated development pro...